ConvaTec Group PLC (CTEC) Receives Average Rating of “Hold” from Analysts
ConvaTec Group PLC (LON:CTEC) has been given a consensus recommendation of “Hold” by the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is GBX 175.40 ($2.29).
CTEC has been the topic of a number of recent research reports. Numis Securities reissued a “buy” rating and issued a GBX 220 ($2.87) target price on shares of ConvaTec Group in a report on Monday, January 21st. JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 135 ($1.76) target price (down previously from GBX 192 ($2.51)) on shares of ConvaTec Group in a report on Monday, February 18th. UBS Group decreased their price objective on ConvaTec Group from GBX 150 ($1.96) to GBX 120 ($1.57) and set a “neutral” rating on the stock in a research note on Tuesday, February 19th. Goldman Sachs Group decreased their price objective on ConvaTec Group from GBX 165 ($2.16) to GBX 160 ($2.09) and set a “neutral” rating on the stock in a research note on Friday, January 18th. Finally, Deutsche Bank decreased their price objective on ConvaTec Group from GBX 180 ($2.35) to GBX 130 ($1.70) and set a “sell” rating on the stock in a research note on Monday, December 10th.
Shares of ConvaTec Group stock traded down GBX 2.40 ($0.03) during trading on Monday, hitting GBX 135.50 ($1.77). 3,192,289 shares of the company’s stock traded hands, compared to its average volume of 5,440,000. The company has a debt-to-equity ratio of 101.69, a current ratio of 2.73 and a quick ratio of 1.72. ConvaTec Group has a 1 year low of GBX 113.25 ($1.48) and a 1 year high of GBX 240.50 ($3.14). The stock has a market capitalization of $2.66 billion and a PE ratio of 12.32.
About ConvaTec Group
ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as for traumatic injury, burns, invasive surgery, and other causes.
Further Reading: Market Capitalization and Individual Investors
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.